K2 BIOCAPITAL

Building Biotech Between China and Global Markets

K2 BioCapital forms, finances, and advises biotech companies built around high-conviction life sciences assets.

We work with Chinese biotechs going global, global biotechs entering China, and investors looking for differentiated biotech opportunities across both markets.

Partner With K2

Shanghai · Boston · San Francisco

What We Do

K2 works where biotech assets, capital, and company formation come together.

NewCo Formation

We help form new companies around differentiated biotech assets, including China-origin programs with global development potential.

Investment & Capital Strategy

For select opportunities, K2 BioCapital can invest directly, support syndication, and work alongside aligned capital partners.

Licensing & BD

We support licensing, partner targeting, transaction strategy, and deal process management for companies moving between China and global markets.

Fractional Leadership

We provide hands-on CBO, CEO, and BD support for biotech companies that need senior leadership before building a full internal team.

Why K2 BioCapital Exists

Strong science does not automatically become a fundable company or a global transaction.

1

Capital Is More Selective

Biotech companies need sharper development plans, cleaner data packages, and credible paths to value inflection.

2

Chinese Assets Need Global Translation

Many Chinese companies have strong programs but need better positioning, transaction structure, and access to the right buyers, investors, and partners.

3

Global Biotechs Need China Optionality

China can support development, CRO access, clinical strategy, financing, and partnerships, but only when the right operating model is chosen.

4

K2 Connects the Pieces

We focus on assets where capital, structure, partners, and operating judgment can create a real company or transaction.

Where We Operate

K2 is built around the China-global biotech corridor.

China & Asia

Relationships across China's biotech, CRO, investor, and clinical development market, with broader connectivity across Singapore, Japan, and Asia.

United States

Operator, venture, and investor network across Boston, San Francisco, Chicago, and major U.S. life sciences hubs.

Global Markets

Support for licensing, market entry, co-investment, NewCo formation, and strategic partnerships across global biotech markets.

Who We Work With

Chinese Biotech Companies

For China-origin companies seeking global partners, licensing transactions, NewCo structures, investor access, or strategic capital.

  • Global BD strategy
  • Asset positioning
  • Partner and investor targeting
  • NewCo and transaction structuring
  • Capital strategy and syndication

Global Biotech Companies

For global biotechs evaluating China as a development, CRO, clinical, financing, or strategic partnership pathway.

  • China-entry strategy
  • CRO and vendor diligence
  • Preclinical and clinical support
  • Strategic China partnerships
  • Local operating coordination

Investors, Family Offices & Strategic Partners

For capital partners seeking curated exposure to China-global biotech opportunities.

  • Co-investment opportunities
  • NewCo formation
  • Vetted biotech assets
  • Diligence support
  • Portfolio BD and value creation

Investment Focus

Selective participation in high-conviction biotech opportunities.

K2 focuses on assets and companies where we can bring more than advice: capital, structure, partners, and operating judgment.

  • Licensing-ready or NewCo-ready assets
  • Preclinical to early clinical programs with global relevance
  • China-origin assets with differentiated data packages
  • Global companies seeking strategic China leverage
  • Oncology, immunology, metabolic disease, rare disease, and platform technologies
  • Opportunities suitable for direct investment, syndication, or venture creation

K2 participates selectively through direct investment, syndication, venture creation, and strategic capital partnerships.

Founder

Irtaza Haider

Founder & Managing Partner, K2 BioCapital

Irtaza is a biotech operator, venture builder, and cross-border investment strategist focused on moving life sciences assets between China and global markets.

  • 2x exited biotech startup operator
  • U.S. biotech VC experience with OMX Ventures and Transform VC
  • China biotech VC and NewCo experience
  • Technology transfer and commercialization experience at Northwestern University
  • Global Executive MBA, Kellogg School of Management
  • Network across U.S., China, and global biotech investors, operators, and strategic partners

Build With K2 BioCapital

K2 works with biotech companies, asset owners, investors, and strategic partners to form, finance, and scale high-potential life sciences opportunities.

Whether the need is capital, partners, licensing, NewCo formation, China access, or transaction support, K2 helps structure the opportunity and move it forward.

irtaza@k2biocapital.vc

K2 BioCapital
Biotech Investment · Venture Creation · Cross-Border Strategy
Shanghai · Boston · San Francisco